Nivolumab plus ipilimumab as neoadjuvant treatment in primary advanced renal cell tumors: Cutting edges for cutting-edge surgery

de Joode, K. (Karlijn), de Ruig-Spakman, J.I. (Jolanda I.), Baktawar, S.S. (Sarwan S.), G.J.H.L. Leenders (Geert), P.C.M.S. Verhagen (Paul) and van der Veldt, A.A.M. (Astrid A.M.)

2020-03-19

Additional Metadata
Persistent URL	doi.org/10.1016/j.urolonc.2020.01.009, hdl.handle.net/1765/126055
Journal	Urologic Oncology
Organisation	Department of Medical Oncology
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	de Joode, K. (Karlijn), de Ruig-Spakman, J.I. (Jolanda I.), Baktawar, S.S. (Sarwan S.), Leenders, G., Verhagen, P., & van der Veldt, A.A.M. (Astrid A.M.). (2020). Nivolumab plus ipilimumab as neoadjuvant treatment in primary advanced renal cell tumors: Cutting edges for cutting-edge surgery. Urologic Oncology. doi:10.1016/j.urolonc.2020.01.009

Publication